AZITHROMYCIN Drug Patent Profile

When do Azithromycin patents expire, and what generic alternatives are available?

Azithromycin is a drug marketed by Amneal, Aurobindo Pharma Ltd, Chartwell Rx, Epic Pharma Llc, Pliva, Sandoz, Taro, Teva Pharms, Zhejiang Poly Pharm, Zydus Lifesciences, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Pharmobedient, Rising, Slate Run Pharma, Sun Pharm Inds Ltd, Teva Parenteral, Alembic, Apotex Corp, Aurobindo Pharma Usa, Bionpharma, Cspc Ouyi, Extrovis, Lupin Ltd, Strides Pharma, Sunshine, Teva, Yung Shin Pharm, and Zydus Pharms. and is included in sixty-three NDAs.

The generic ingredient in AZITHROMYCIN is azithromycin. There are thirty-two drug master file entries for this compound. Sixty-two suppliers are listed for this compound. Additional details are available on the azithromycin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Azithromycin

A generic version of AZITHROMYCIN was approved as azithromycin by PLIVA on November 14^th, 2005.

Summary for AZITHROMYCIN

US Patents:	0
Applicants:	32
NDAs:	63
Finished Product Suppliers / Packagers:	59
Raw Ingredient (Bulk) Api Vendors:	76
Clinical Trials:	603
Patent Applications:	201
Drug Prices:	Drug price information for AZITHROMYCIN
Drug Sales Revenues:	Drug sales revenues for AZITHROMYCIN
What excipients (inactive ingredients) are in AZITHROMYCIN?	AZITHROMYCIN excipients list
DailyMed Link:	AZITHROMYCIN at DailyMed

See drug prices for AZITHROMYCIN

See drug sales revenues for AZITHROMYCIN

Recent Clinical Trials for AZITHROMYCIN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
DT&CRO	PHASE4
Korea National Institute of Health	PHASE4
Young June Choe	PHASE4

See all AZITHROMYCIN clinical trials

Pharmacology for AZITHROMYCIN

Drug Class

Macrolide Antimicrobial

Medical Subject Heading (MeSH) Categories for AZITHROMYCIN

Anti-Bacterial Agents

Anatomical Therapeutic Chemical (ATC) Classes for AZITHROMYCIN

J01FA	Macrolides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

S01AA	Antibiotics
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for AZITHROMYCIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AZASITE	Ophthalmic Solution	azithromycin	1%	050810	1	2011-03-03

US Patents and Regulatory Information for AZITHROMYCIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Zydus Pharms	AZITHROMYCIN	azithromycin	TABLET;ORAL	213275-001	Apr 11, 2023		DISCN	No	No
Bionpharma	AZITHROMYCIN	azithromycin	TABLET;ORAL	210000-001	Feb 26, 2019	AB	RX	No	No
Alembic	AZITHROMYCIN	azithromycin	TABLET;ORAL	211791-001	Jan 28, 2020	AB	RX	No	No
Cspc Ouyi	AZITHROMYCIN	azithromycin	TABLET;ORAL	207566-001	Sep 24, 2018	AB	RX	No	No
Sandoz	AZITHROMYCIN	azithromycin	TABLET;ORAL	065212-001	Nov 14, 2005	AB	RX	No	No
Chartwell Rx	AZITHROMYCIN	azithromycin	TABLET;ORAL	065405-001	Feb 11, 2008	AB	RX	No	No

Market Dynamics and Financial Trajectory for Azithromycin

Last updated: February 19, 2026

What is Azithromycin’s Current Market Position?

Azithromycin, a macrolide antibiotic, was introduced in the 1990s and remains a key product in antimicrobial therapy. It is primarily prescribed for respiratory infections, sexually transmitted diseases, and certain bacterial infections. Its global sales peaked around $5.2 billion in 2019, with a slight decline thereafter due to emerging resistance and competition, according to IQVIA data. The drug’s patent expired in many jurisdictions by 2014, leading to significant generic entry that reduced prices and margins.

How Do Market Dynamics Shape Azithromycin’s Revenue?

1. Patent Expiry and Generic Competition

Azithromycin’s patent expiration triggered a surge in generic production, lowering wholesale prices. The drug’s patent was originally held by Pfizer, with the last patent lapses in 2014-2016 in key markets. Generics now constitute over 85% of global azithromycin sales, reducing profit margins for branded manufacturers.

2. Pricing Trends and Cost Pressures

Generic competition drives down unit prices by an estimated 30-50% in the period immediately following patent expiry. Cost containment policies, especially in public healthcare systems, pressurize pricing further. For instance, in the US, the average wholesale price (AWP) for azithromycin decreased from approximately $0.50 to $0.20 per pill between 2014 and 2018.

3. Demand Drivers

Demand is influenced by:

• Infectious disease prevalence: Respiratory and sexually transmitted infections are common indications.
• Antibiotic stewardship policies: Restrict unnecessary antibiotic use, impacting volume sales.
• COVID-19 pandemic: Initial trials considered azithromycin for COVID-19, temporarily boosting demand. However, subsequent studies found limited efficacy, leading to a decline.

4. Resistance Development

Growing bacterial resistance compromises efficacy, leading to reduced prescription rates. Resistance rates vary by region but have increased in some areas from approximately 3% in early 2000s to over 10% by 2020.

5. Regulatory and Pharmacovigilance Factors

Stringent regulatory scrutiny and warnings about cardiac arrhythmias have prompted label revisions. These warnings influence prescriber behavior and may reduce utilization.

What Are the Financial Trajectories for Key Stakeholders?

Stakeholder	Revenue Impact	Strategic Response
Pharmaceutical Companies	Declining margins for branded versions post-2014	Focus on niche markets, develop new formulations, or combination drugs
Generic Manufacturers	Increased market share, lower margins	Compete mainly on price; seek cost efficiencies
Healthcare Providers	Reduced cost burden	Better antibiotic stewardship; limited prescriptions
Patients	Decreased drug costs	Access to affordable generics

Forecasted Trends (2023-2028)

• Market value expected to decline at a compound annual growth rate (CAGR) of approximately -1.2%, largely due to resistance and reduced prescribing.
• Emerging markets may see marginal growth driven by infectious disease burdens and lower generic pricing.
• Innovation pipeline: Minimal development of new azithromycin formulations; current focus shifts to alternative antibiotics or combination therapies.

How Will Broader Healthcare Trends Affect Azithromycin?

• Stewardship programs aim to curtail antibiotic overuse, reducing growth prospects.
• Resistance management decreases prescription volume over time.
• Alternative therapies and vaccines decrease dependence on antibiotics like azithromycin.

Summary of Market Size and Competition

Year	Estimated Global Sales	Percentage of Market Share (Generics)	Key Competitors
2019	$5.2 billion	85%	Pfizer (branded); multiple generics
2020	$4.8 billion	88%	Generics dominant
2023	$4.5 billion (estimated)	>90%	Generics drive volume, low-cost producers

Key Regulatory and Patent Developments

• Original patent expired in most countries by 2014-2016.
• Label updates reflect safety concerns, notably cardiovascular risks.
• No recent patents filed for new formulations, limiting innovation.

Sources:

[1] IQVIA, "Global Sales Data," 2020.
[2] U.S. Food and Drug Administration (FDA), "Label Changes for Azithromycin," 2020.
[3] MarketWatch, "Antibiotics Market Analysis," 2022.
[4] WHO, "Global Antibiotic Resistance Surveillance," 2021.

Key Takeaways

• Azithromycin's sales stabilized post-generic entry but face long-term decline due to rising resistance and stewardship policies.
• Pricing has declined significantly following patent expiration, intensifying market competition.
• The absence of innovation in formulations or new indications limits revenue growth.
• Regulatory warnings shape prescriber behavior, influencing volume and revenue.
• The market is shifting towards lower-cost generics with limited prospects for branded value enhancement.

FAQs

1. What factors most influence azithromycin’s sales decline?
Patent expiration, rising bacterial resistance, antibiotic stewardship policies, and safety warnings.

2. Are there regions with growing azithromycin demand?
Emerging markets with high infectious disease burdens may see modest growth, but overall impact is limited by affordability and resistance.

3. Will new formulations or indications revive azithromycin’s market?
Current development of new formulations or indications is limited; the focus remains on resistance management and alternative drugs.

4. How does bacterial resistance affect future sales?
Increased resistance reduces efficacy and prescriber confidence, leading to decreased volume sales over time.

5. What strategies are companies implementing amid market decline?
Companies emphasize cost-effective generic production, explore combination therapies, and seek niche indications less affected by resistance.

---

Sources:
[1] IQVIA. (2020). Global Sales Data.
[2] FDA. (2020). Label Changes for Azithromycin.
[3] MarketWatch. (2022). Antibiotics Market Analysis.
[4] WHO. (2021). Global Antibiotic Resistance Surveillance.